Cited by 872Computational Drug Discovery MethodsBioinformatics and Genomic NetworksBiomedical Text Mining and Ontologies

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Trends in the exploitation of novel drug targets

Rask-Andersen, Mathias, Almén, Markus Sällman, Schiöth, Helgi B.·2011·Nature Reviews Drug Discovery

DOI 10.1038/nrd3478

Open this paper in CoChat — free account

Abstract

The discovery and exploitation of new drug targets is a key focus for both the pharmaceutical industry and academic biomedical research. To provide an insight into trends in the exploitation of new drug targets, we have analysed the drugs that were approved by the US Food and Drug Administration during the past three decades and examined the interactions of these drugs with therapeutic targets that are encoded by the human genome, using the DrugBank database and extensive manual curation. We have identified 435 effect-mediating drug targets in the human genome, which are modulated by 989 unique drugs, through 2,242 drug-target interactions. We also analyse trends in the introduction of drugs that modulate previously unexploited targets, and discuss the network pharmacology of the drugs in our data set.

Integrity signals

Registry

Crossref · 10.1038/nrd3478

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Goodman & Gilman's The Pharmacological Basis of Therapeutics
Brunton, L. L. (1985) · Cited by 7,321
Goodman and Gilman's the Pharmacological Basis of Therapeutics
Stigelman, W. H., & Pharm, D. (1986) · Military Medicine · doi:10.1093/milmed/151.1.386 · Cited by 6,796
Network pharmacology: the next paradigm in drug discovery
Hopkins, A. L. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.118 · Cited by 4,622
DrugBank: a comprehensive resource for in silico drug discovery and exploration
Wishart, D. S. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkj067 · Cited by 3,892
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566
How many drug targets are there?
Overington, J. P., Al-Lazikani, B., & Hopkins, A. L. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2199 · Cited by 3,505
The druggable genome
Hopkins, A. L., & Groom, C. R. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd892 · Cited by 3,305
DrugBank: a knowledgebase for drugs, drug actions and drug targets
Wishart, D. S., Knox, C., Guo, A. C., Cheng, D., Shrivastava, S., Tzur, D., Gautam, B., & Hassanali, M. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm958 · Cited by 2,896
Drug Discovery: A Historical Perspective
Drews, J. (2000) · Science · doi:10.1126/science.287.5460.1960 · Cited by 2,805
DrugBank 3.0: a comprehensive resource for 'Omics' research on drugs
Knox, C., Law, V., Jewison, T., Liu, P., Ly, S., Frolkis, A., Pon, A., Banco, K., Mak, C., Neveu, V., et al. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq1126 · Cited by 1,832

Flagged first, then by citations

Show all 18 references

Sorted by citations

Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160
Discovery and resupply of pharmacologically active plant-derived natural products: A review
Atanasov, A. G., Waltenberger, B., Pferschy‐Wenzig, E., Linder, T., Wawrosch, C., Uhrín, P., Temml, V., Wang, L., Schwaiger, S., Heiß, E. H., et al. (2015) · Biotechnology Advances · doi:10.1016/j.biotechadv.2015.08.001 · Cited by 3,105
Trends in GPCR drug discovery: new agents, targets and indications
Hauser, A. S., Attwood, M. M., Rask‐Andersen, M., Schiöth, H. B., & Gloriam, D. E. I. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.178 · Cited by 2,714
Self-citation
A comprehensive map of molecular drug targets
Santos, R., Ursu, O., Gaulton, A., Bento, A. P., Donadi, R. S., Bologa, C. G., Karlsson, A., Al-Lazikani, B., Hersey, A., Oprea, T. I., et al. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.230 · Cited by 2,427
Monitoring Drug Target Engagement in Cells and Tissues Using the Cellular Thermal Shift Assay
Molina, D. M., Jafari, R., Ignatushchenko, M., Seki, T., Larsson, E. A., Dan, C., Sreekumar, L., Cao, Y., & Nordlund, P. (2013) · Science · doi:10.1126/science.1233606 · Cited by 2,261
CB-Dock2: improved protein–ligand blind docking by integrating cavity detection, docking and homologous template fitting
Liu, Y., Yang, X., Gan, J., Chen, S., Xiao, Z. J., & Cao, Y. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac394 · Cited by 2,255
Polypharmacology: Challenges and Opportunities in Drug Discovery: Miniperspective
Anighoro, A., Bajorath, J., & Rastelli, G. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5006463 · Cited by 1,131
Three-Dimensional Cell Cultures in Drug Discovery and Development
Fang, Y., & Eglen, R. M. (2017) · SLAS Discovery · doi:10.1177/1087057117696795 · Cited by 849
The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands
Pawson, A. J., Sharman, J. L., Benson, H. E., Faccenda, E., Alexander, S. P. H., Buneman, O. P., Davenport, A. P., McGrath, J. C., Peters, J. A., Southan, C., et al. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt1143 · Cited by 845
Trends in kinase drug discovery: targets, indications and inhibitor design
Attwood, M. M., Fabbro, D., Sokolov, A. V., Knapp, S., & Schiöth, H. B. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00252-y · Cited by 850
Self-citation
Targeted protein degradation by PROTACs
Neklesa, T. K., Winkler, J. D., & Crews, C. M. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.027 · Cited by 599
How Ligands Illuminate GPCR Molecular Pharmacology
Wacker, D., Stevens, R. C., & Roth, B. L. (2017) · Cell · doi:10.1016/j.cell.2017.07.009 · Cited by 560
The emerging mutational landscape of G proteins and G-protein-coupled receptors in cancer
O’Hayre, M., Vázquez‐Prado, J., Kufareva, I., Stawiski, E. W., Handel, T. M., Seshagiri, S., & Gutkind, J. S. (2013) · Nature reviews. Cancer · doi:10.1038/nrc3521 · Cited by 559
The Concise Guide to PHARMACOLOGY 2013/14: G Protein‐Coupled Receptors
Alexander, S. P. H., Benson, H. E., Faccenda, E., Pawson, A. J., Sharman, J. L., Spedding, M., Peters, J. A., Harmar, A. J., & Collaborators, C. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12445 · Cited by 561
PGC1α drives NAD biosynthesis linking oxidative metabolism to renal protection
Tran, M. T., Zsengellér, Z. K., Berg, A. H., Khankin, E. V., Bhasin, M., Kim, W., Clish, C. B., Stillman, I. E., Karumanchi, S. A., Rhee, E. P., et al. (2016) · Nature · doi:10.1038/nature17184 · Cited by 546
DGIdb: mining the druggable genome
Griffith, M., Griffith, O. L., Coffman, A. C., Weible, J. V., McMichael, J. F., Spies, N. C., Koval, J., Das, I., Callaway, M. B., Eldred, J. M., et al. (2013) · Nature Methods · doi:10.1038/nmeth.2689 · Cited by 538
Therapeutic target database update 2018: enriched resource for facilitating bench-to-clinic research of targeted therapeutics
Li, Y., Yu, C. Y., Li, X. X., Zhang, P., Tang, J., Yang, Q., Fu, T., Zhang, X., Cui, X., Tu, G., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx1076 · Cited by 529
The Transporter Classification Database
Saier, M. H., Reddy, V. S., Tamang, D. G., & Västermark, Å. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt1097 · Cited by 510
Drug discovery in pharmaceutical industry: productivity challenges and trends
Khanna, I. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.05.007 · Cited by 479
Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery
Zhu, F., Shi, Z., Qin, C., Tao, L., Liu, X., Xu, F., Zhang, L., Song, Y., Liu, X., Zhang, J., et al. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr797 · Cited by 479
Surface plasmon resonance spectroscopy for characterisation of membrane protein–ligand interactions and its potential for drug discovery
Patching, S. G. (2013) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2013.04.028 · Cited by 487
Impact of a five-dimensional framework on R&D productivity at AstraZeneca
Morgan, P., Brown, D. G., Lennard, S., Anderton, M. J., Barrett, J. C., Eriksson, U. G., Fidock, M. D., Hamrén, B., Johnson, A. G., March, R. E., et al. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.244 · Cited by 470
Recent developments of HDAC inhibitors: Emerging indications and novel molecules
Bondarev, A. D., Attwood, M. M., Jonsson, J., Chubarev, V. N., Tarasov, V. V., & Schiöth, H. B. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14889 · Cited by 451
Self-citation
Diversity-oriented synthesis: producing chemical tools for dissecting biology
Connor, C. J. O., Beckmann, H. S. G., & Spring, D. R. (2012) · Chemical Society Reviews · doi:10.1039/c2cs35023h · Cited by 438
Phenotypic screens as a renewed approach for drug discovery
Zheng, W., Thorne, N., & McKew, J. C. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.07.001 · Cited by 438
Probiotics, prebiotics, and postbiotics in health and disease
Ji, J., Jin, W., Liu, S., Jiao, Z., & Li, X. (2023) · MedComm · doi:10.1002/mco2.420 · Cited by 449
DGIdb 2.0: mining clinically relevant drug–gene interactions
Wagner, A. H., Coffman, A. C., Ainscough, B. J., Spies, N. C., Skidmore, Z. L., Campbell, K. M., Krysiak, K., Pan, D., McMichael, J. F., Eldred, J. M., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1165 · Cited by 413
Chemical proteomics approaches for identifying the cellular targets of natural products
Wright, M. H., & Sieber, S. A. (2016) · Natural Product Reports · doi:10.1039/c6np00001k · Cited by 400
Targeting EMT in cancer: opportunities for pharmacological intervention
Davis, F. M., Stewart, T. A., Thompson, E. W., & Monteith, G. R. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.06.006 · Cited by 367
How Beyond Rule of 5 Drugs and Clinical Candidates Bind to Their Targets
Doak, B. C., Zheng, J., Dobritzsch, D., & Kihlberg, J. O. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01286 · Cited by 348
Drugging Membrane Protein Interactions
Yin, H. H., & Flynn, A. D. (2016) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-092115-025322 · Cited by 362
A systematic analysis of FDA-approved anticancer drugs
Sun, J., Wei, Q., Zhou, Y., Wang, J., Liu, Q., & Xu, H. (2017) · BMC Systems Biology · doi:10.1186/s12918-017-0464-7 · Cited by 334
Signaling pathways in cancer metabolism: mechanisms and therapeutic targets
You, M., Xie, Z., Zhang, N., Zhang, Y., Xiao, D., Liu, S., Zhuang, W., Li, L., & Tao, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01442-3 · Cited by 317
Mycobacterium tuberculosis-Driven Targeted Recalibration of Macrophage Lipid Homeostasis Promotes the Foamy Phenotype
Singh, V., Jamwal, S., Jain, R., Verma, P., Gokhale, R., & Rao, K. V. S. (2012) · Cell Host & Microbe · doi:10.1016/j.chom.2012.09.012 · Cited by 295
Biased agonism: An emerging paradigm in GPCR drug discovery
Ranković, Z., Brust, T. F., & Bohn, L. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.12.024 · Cited by 285
The Druggable Genome: Evaluation of Drug Targets in Clinical Trials Suggests Major Shifts in Molecular Class and Indication
Rask-Andersen, M., Masuram, S., & Schiöth, H. B. (2014) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011613-135943 · Cited by 282
Self-citation
Recent Advances in Developing Small Molecules Targeting RNA
Guan, L., & Disney, M. D. (2011) · ACS Chemical Biology · doi:10.1021/cb200447r · Cited by 282
GPCR drug discovery: integrating solution NMR data with crystal and cryo-EM structures
Shimada, I., Ueda, T., Kofuku, Y., Eddy, M. T., & Wüthrich, K. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.180 · Cited by 282
When Quality Beats Quantity: Decision Theory, Drug Discovery, and the Reproducibility Crisis
Scannell, J. W., & Bosley, J. (2016) · PLOS ONE · doi:10.1371/journal.pone.0147215 · Cited by 279
G protein-coupled receptors for energy metabolites as new therapeutic targets
Blad, C. C., Tang, C., & Offermanns, S. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3777 · Cited by 277
Distinct profiles of functional discrimination among G proteins determine the actions of G protein–coupled receptors
Masuho, I., Ostrovskaya, O. I., Kramer, G. M., Jones, C. D., Xie, K., & Martemyanov, K. A. (2015) · Science Signaling · doi:10.1126/scisignal.aab4068 · Cited by 266
Network pharmacology of cancer: From understanding of complex interactomes to the design of multi-target specific therapeutics from nature
Poornima, P., Kumar, J. D., Zhao, Q., Blunder, M., & Efferth, T. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.06.018 · Cited by 254
PACKMOL-Memgen: A Simple-To-Use, Generalized Workflow for Membrane-Protein–Lipid-Bilayer System Building
Schott‐Verdugo, S., & Gohlke, H. (2019) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.9b00269 · Cited by 249
An ALOX12–12-HETE–GPR31 signaling axis is a key mediator of hepatic ischemia–reperfusion injury
Zhang, X., Cheng, X., Yan, Z., Fang, J., Wang, X., Wang, W., Liu, Z., Shen, L., Zhang, P., Wang, P., et al. (2017) · Nature Medicine · doi:10.1038/nm.4451 · Cited by 245
Drug Target Prediction and Repositioning Using an Integrated Network-Based Approach
Emig, D., Ivliev, A. E., Pustovalova, O., Lancashire, L., Bureeva, S. V., Nikolsky, Y., & Bessarabova, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060618 · Cited by 242
Improving the odds of drug development success through human genomics: modelling study
Hingorani, A. D., Kuan, V., Finan, C., Krüger, F. A., Gaulton, A., Chopade, S., Sofat, R., MacAllister, R. J., Overington, J. P., Hemingway, H., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-54849-w · Cited by 252
What makes a good drug target?
Gashaw, I., Ellinghaus, P., Sommer, A., & Asadullah, K. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.09.007 · Cited by 248
Integrating artificial intelligence in drug discovery and early drug development: a transformative approach
Ocaña, A., Pandiella, A., Privat, C., Bravo, I., Luengo-Oroz, M. A., Amir, E., & Győrffy, B. (2025) · Biomarker Research · doi:10.1186/s40364-025-00758-2 · Cited by 248
Therapeutic Strategies to Inhibit MYCPreprint
McKeown, M. R., & Bradner, J. E. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a014266 · Cited by 231
The SLC transporter in nutrient and metabolic sensing, regulation, and drug development
Zhang, Y., Zhang, Y., Sun, K., Meng, Z., & Chen, L. (2018) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjy052 · Cited by 218
Using data‐independent, high‐resolution mass spectrometry in protein biomarker research: Perspectives and clinical applications
Sajic, T., Liu, Y., & Aebersold, R. H. (2014) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.201400117 · Cited by 214
The Origin of GPCRs: Identification of Mammalian like Rhodopsin, Adhesion, Glutamate and Frizzled GPCRs in Fungi
Krishnan, A., Almén, M. S., Fredriksson, R., & Schiöth, H. B. (2012) · PLoS ONE · doi:10.1371/journal.pone.0029817 · Cited by 204
Self-citation
Genetic evidence that β-arrestins are dispensable for the initiation of β 2 -adrenergic receptor signaling to ERK
O’Hayre, M., Eichel, K., Avino, S., Zhao, X., Steffen, D. J., Feng, X., Kawakami, K., Aoki, J., Messer, K. S., Sunahara, R. K., et al. (2017) · Science Signaling · doi:10.1126/scisignal.aal3395 · Cited by 201
Novel Allosteric Modulators of G Protein-coupled Receptors
Gentry, P. R., Sexton, P. M., & Christopoulos, A. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.r115.662759 · Cited by 199
Optical control of neuronal ion channels and receptors
Paoletti, P., Ellis‐Davies, G. C. R., & Mourot, A. (2019) · Nature reviews. Neuroscience · doi:10.1038/s41583-019-0197-2 · Cited by 203
G Protein–Coupled Receptor Deorphanizations
Civelli, O., Reinscheid, R. K., Zhang, Y., Wang, Z., Fredriksson, R., & Schiöth, H. B. (2011) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010611-134548 · Cited by 199
Self-citation
Mitigating risk in academic preclinical drug discovery
Dahlin, J. L., Inglese, J., & Walters, M. A. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4578 · Cited by 192
Orphan G protein-coupled receptors (GPCRs): biological functions and potential drug targets
Tang, X., Wang, Y., Li, D.-L., Luo, J., & Liu, M. (2012) · Acta Pharmacologica Sinica · doi:10.1038/aps.2011.210 · Cited by 200
Computational prediction of protein interfaces: A review of data driven methods
Xue, L. C., Dobbs, D. L., Bonvin, A. M. J. J., & Honavar, V. (2015) · FEBS Letters · doi:10.1016/j.febslet.2015.10.003 · Cited by 184
Advances in kinase targeting: current clinical use and clinical trials
Rask‐Andersen, M., Zhang, J., Fabbro, D., & Schiöth, H. B. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.09.007 · Cited by 186
Self-citation
Revolution of Alzheimer Precision Neurology. Passageway of Systems Biology and Neurophysiology
Hampel, H. J., (APMI), F. T. A. P. M. I., Toschi, N., Babiloni, C., Baldacci, F., Black, K. L., Bokde, A. L. W., Bun, R. S., Cacciola, F., Cavedo, E., et al. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-179932 · Cited by 184
Lycium ruthenicum studies: Molecular biology, Phytochemistry and pharmacology
Wang, H., Li, J., Tao, W., Zhang, X., Gao, X., Yong, J., Zhao, J., Zhang, L., Li, Y., & Duan, J. (2017) · Food Chemistry · doi:10.1016/j.foodchem.2017.08.026 · Cited by 180
Structure-inspired design of β-arrestin-biased ligands for aminergic GPCRs
McCorvy, J. D., Butler, K. V., Kelly, B., Rechsteiner, K., Karpiak, J. D., Betz, R. M., Kormos, B. L., Shoichet, B. K., Dror, R. O., Jin, J. J., et al. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2527 · Cited by 175
A systematic approach to identify novel cancer drug targets using machine learning, inhibitor design and high-throughput screening
Jeon, J., Nim, S., Teyra, J., Datti, A., Wrana, J. L., Sidhu, S. S., Moffat, J., & Kim, P. M. (2014) · Genome Medicine · doi:10.1186/s13073-014-0057-7 · Cited by 174
Large scale comparison of QSAR and conformal prediction methods and their applications in drug discovery
Bosc, N., Atkinson, F. L., Félix, E., Gaulton, A., Hersey, A., & Leach, A. R. (2019) · Journal of Cheminformatics · doi:10.1186/s13321-018-0325-4 · Cited by 167
The role of lipid-activated nuclear receptors in shaping macrophage and dendritic cell function: From physiology to pathology
Kiss, M., Czimmerer, Z., & Nagy, L. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.05.044 · Cited by 166
Functional Dynamics of Deuterated β2‐Adrenergic Receptor in Lipid Bilayers Revealed by NMR Spectroscopy
Kofuku, Y., Ueda, T., Okude, J., Shiraishi, Y., Kondo, K., Mizumura, T., Suzuki, S., & Shimada, I. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201406603 · Cited by 161
Allosteric Modulation of Class A GPCRs: Targets, Agents, and Emerging Concepts
Wold, E. A., Chen, J., Cunningham, K. A., & Zhou, J. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00875 · Cited by 161
Solute Carrier Transporters as Potential Targets for the Treatment of Metabolic Disease
Schumann, T., König, J., Henke, C., Willmes, D. M., Bornstein, S. R., Jordan, J., Fromm, M. F., & Birkenfeld, A. L. (2019) · Pharmacological Reviews · doi:10.1124/pr.118.015735 · Cited by 157
Evolutionary origin of amino acid transporter families SLC32, SLC36 and SLC38 and physiological, pathological and therapeutic aspects
Schiöth, H. B., Roshanbin, S., Hägglund, M. G. A., & Fredriksson, R. (2013) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2012.07.012 · Cited by 150
Self-citation
Heteromeric MT 1 /MT 2 Melatonin Receptors Modulate Photoreceptor Function
Baba, K., Benleulmi‐Chaachoua, A., Journé, A., Kamal, M. T., Guillaume, J., Dussaud, S., Gbahou, F., Yettou, K., Liu, C., Contreras‐Alcantara, S., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004302 · Cited by 145
Cell-SELEX Technology
Ohuchi, S. P. (2012) · BioResearch open access · doi:10.1089/biores.2012.0253 · Cited by 150
Decoding Signaling and Function of the Orphan G Protein–Coupled Receptor GPR17 with a Small-Molecule Agonist
Hennen, S., Wang, H., Peters, L., Merten, N., Simon, K., Spinrath, A., Blättermann, S., Akkari, R., Schrage, R., Schröder, R. J., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004350 · Cited by 146
Two-Photon Small Molecule Enzymatic Probes
Qian, L., Li, L., & Yao, S. Q. (2016) · Accounts of Chemical Research · doi:10.1021/acs.accounts.5b00512 · Cited by 143
Peptide-based protease inhibitors from plants
Hellinger, R., & Gruber, C. W. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.05.026 · Cited by 140
New Insights into Aptamers: An Alternative to Antibodies in the Detection of Molecular Biomarkers
Domšicová, M., Korčeková, J., Poturnayová, A., & Breier, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25136833 · Cited by 138
Properties of Protein Drug Target Classes
Bull, S. C., & Doig, A. J. (2015) · PLoS ONE · doi:10.1371/journal.pone.0117955 · Cited by 146
Molecular Connections between Cancer Cell Metabolism and the Tumor Microenvironment
Justus, C., Sanderlin, E. J., & Yang, L. V. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160511055 · Cited by 139
Learning from the past and looking to the future: emerging perspectives for improving the treatment of psychiatric disorders
Millan, M. J., Goodwin, G. M., Meyer-Lindenberg, A., & Ove Ögren, S. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.01.016 · Cited by 132
Pharmacological treatment of migraine: Drug classes, mechanisms of action, clinical trials and new treatments
Zobdeh, F., Kraiem, A. B., Attwood, M. M., Chubarev, V. N., Tarasov, V. V., Schiöth, H. B., & Mwinyi, J. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15657 · Cited by 139
Self-citation
Towards a mechanistic understanding of reciprocal drug–microbiome interactions
Zimmermann, M., Patil, K. R., Typas, A., & Maier, L. (2021) · Molecular Systems Biology · doi:10.15252/msb.202010116 · Cited by 124
G-Protein-Coupled Receptor Signaling in CiliaPreprint
Mykytyn, K., & Askwith, C. C. (2017) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a028183 · Cited by 134
Therapeutic target database update 2014: a resource for targeted therapeutics
Chu, Q., Zhang, C., Zhu, F., Xu, F., Chen, S. Y., Zhang, P., Li, Y., Yang, S. Y., Wei, Y., Tao, L., et al. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt1129 · Cited by 122
What Can Crystal Structures of Aminergic Receptors Tell Us about Designing Subtype-Selective Ligands?
Michino, M., Beuming, T., Donthamsetti, P., Newman, A. H., Javitch, J. A., & Shi, L. (2014) · Pharmacological Reviews · doi:10.1124/pr.114.009944 · Cited by 118
Chemosensing Ensembles for Monitoring Biomembrane Transport in Real Time
Ghale, G., Lanctôt, A. G., Kreissl, H. T., Jacob, M. H., Weingart, H., Winterhalter, M., & Nau, W. M. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201309583 · Cited by 116
Drug Target Protein-Protein Interaction Networks: A Systematic Perspective
Feng, Y., Wang, Q., & Wang, T. (2017) · BioMed Research International · doi:10.1155/2017/1289259 · Cited by 120
Dynamic tuneable G protein-coupled receptor monomer-dimer populations
Dijkman, P. M., Castell, O. K., Goddard, A. D., Muñoz-García, J. C., de Graaf, C., Wallace, M. I., & Watts, A. G. (2018) · Nature Communications · doi:10.1038/s41467-018-03727-6 · Cited by 116
What makes a good drug target?
Gashaw, I., Ellinghaus, P., Sommer, A., & Asadullah, K. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.12.008 · Cited by 121
Labeling and Single-Molecule Methods To Monitor G Protein-Coupled Receptor Dynamics
Tian, H., Fürstenberg, A., & Huber, T. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00084 · Cited by 114
Application of omics- and multi-omics-based techniques for natural product target discovery
Zhang, H., Lv, C., Zhang, L., Guo, X., Shen, Y., Nagle, D. G., Zhou, Y., Liu, S., Zhang, W., & Luan, X. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111833 · Cited by 115
Treatment of ADHD: Drugs, psychological therapies, devices, complementary and alternative methods as well as the trends in clinical trials
Nazarova, V. A., Sokolov, A. V., Chubarev, V. N., Tarasov, V. V., & Schiöth, H. B. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1066988 · Cited by 111
Self-citation
Ligand-Dependent Activation and Deactivation of the Human Adenosine A2AReceptor
Li, J., Jonsson, A. L., Beuming, T., Shelley, J. C., & Voth, G. A. (2013) · Journal of the American Chemical Society · doi:10.1021/ja404391q · Cited by 113
Target identification of natural products and bioactive compounds using affinity-based probes
Pan, S., Zhang, H., Wang, C., Yao, S. C. L., & Yao, S. Q. (2015) · Natural Product Reports · doi:10.1039/c5np00101c · Cited by 110
Marine natural products with anti-inflammatory activity
Cheung, R. C. F., Ng, T. B., Wong, J. H., Chen, Y., & Chan, W. (2015) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-015-7244-3 · Cited by 112
Soluble ligands as drug targets
Attwood, M. M., Jonsson, J., Rask‐Andersen, M., & Schiöth, H. B. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0078-4 · Cited by 112
Self-citation
PyDPI: Freely Available Python Package for Chemoinformatics, Bioinformatics, and Chemogenomics Studies
Cao, D., Liang, Y., Yan, J., Tan, G., Xu, Q., & Liu, S. (2013) · Journal of Chemical Information and Modeling · doi:10.1021/ci400127q · Cited by 110
Modular detergents tailor the purification and structural analysis of membrane proteins including G-protein coupled receptors
Urner, L. H., Liko, I., Yen, H.-Y., Hoi, K.-K., Bolla, J. R., Gault, J., Almeida, F. G., Schweder, M.-P., Shutin, D., Ehrmann, S., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14424-8 · Cited by 107
Medium-chain fatty acids modulate myocardial function via a cardiac odorant receptor
Jovancevic, N., Dendorfer, A., Matzkies, M., Kovarova, M., Heckmann, J. C., Osterloh, M., Boehm, M., Weber, L., Nguemo, F., Semmler, J., et al. (2017) · Basic Research in Cardiology · doi:10.1007/s00395-017-0600-y · Cited by 107
Diindolylmethane Derivatives: Potent Agonists of the Immunostimulatory Orphan G Protein-Coupled Receptor GPR84
Pillaiyar, T., Köse, M., Sylvester, K., Weighardt, H., Thimm, D., Borges, G., Förster, I., von Kügelgen, I., & Müller, C. E. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01593 · Cited by 107
Ligand Binding Ensembles Determine Graded Agonist Efficacies at a G Protein-coupled Receptor
Böck, A., Bermúdez, M., Krebs, F., Matera, C., Chirinda, B., Sydow, D., Dallanoce, C., Holzgrabe, U., Amici, M. D., Lohse, M. J., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.735431 · Cited by 104

Authors: Rask-Andersen, M., Almén, M. S., & Schiöth, H. B.
Affiliations: Uppsala University (SE)
Corresponding author: Schiöth, Helgi B.
ORCID: Almén, Markus Sällman
Schiöth, Helgi B.
Venue: Nature Reviews Drug Discovery
Publisher: Springer Science and Business Media LLC
Published: 2011-08
Volume: 10
Issue: 8
Pages: 579-590
ISSN: 1474-1776 (ISSN-L)
1474-1784
DOI: 10.1038/nrd3478
OpenAlex: W2029335938
Cited by: 853
References: 18
Citations by year: 2026: 15 · 2025: 35 · 2024: 40 · 2023: 35 · 2022: 50 · 2021: 36 · 2020: 45 · 2019: 63 · 2018: 80 · 2017: 83 · 2016: 82 · 2015: 91 · 2014: 71 · 2013: 69 · 2012: 45
FWCI: 59.67
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Nature Reviews Drug Discovery (publishedVersion)
PubMed (publishedVersion)
Funders: Brain Research Foundation
Vetenskapsrådet
Topics: Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bioinformatics and Genomic Networks
Health Sciences › Medicine › Health Informatics › Biomedical Text Mining and Ontologies
Keywords: novel drug targets, drug-target interactions, FDA-approved drugs, network pharmacology, DrugBank
MeSH terms: Humans, United States, United States Food and Drug Administration, Genome, Human, Databases, Factual, Drug Approval, Receptors, G-Protein-Coupled, Drug Discovery

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Trends in the exploitation of novel drug targets

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks